MEDA Pharma GmbH & Co. KG Sustainability Profile
MEDA Pharma GmbH & Co. KG, a prominent player in the pharmaceutical industry, is headquartered in Germany and operates extensively across Europe and beyond. Founded in 1993, the company has established itself as a leader in the development and distribution of prescription and over-the-counter medications, particularly in the fields of dermatology, respiratory health, and pain management. With a commitment to innovation, MEDA Pharma offers a diverse portfolio of unique products that cater to the specific needs of patients and healthcare professionals. The company’s focus on high-quality formulations and patient-centric solutions has earned it a strong market position and recognition for excellence in the pharmaceutical sector. Through strategic partnerships and a robust distribution network, MEDA Pharma continues to expand its reach and impact in the healthcare landscape.
DitchCarbon Score
How does MEDA Pharma GmbH & Co. KG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
MEDA Pharma GmbH & Co. KG's score of 42 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
MEDA Pharma GmbH & Co. KG, headquartered in Germany, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Viatris Inc., which may influence its climate commitments and reporting practices. While there are no documented reduction targets or specific climate pledges from MEDA Pharma, it is important to note that any potential climate initiatives or targets would likely be aligned with those set by its parent company, Viatris Inc. This includes commitments to sustainability and emissions reduction that may be cascaded down through the corporate structure. As a subsidiary, MEDA Pharma's climate strategy may reflect Viatris Inc.'s broader goals, which are informed by industry standards and best practices. However, without specific data or commitments from MEDA Pharma itself, it is challenging to provide a detailed overview of its carbon emissions and climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 302,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 354,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is MEDA Pharma GmbH & Co. KG's Industry?
How Carbon Intensive is MEDA Pharma GmbH & Co. KG's Location?
MEDA Pharma GmbH & Co. KG's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
MEDA Pharma GmbH & Co. KG has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.